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Background: We analyzed the relationship between prostate cancer outcomes and pretreatment clinical factors
and developed a prognostic nomogram of overall survival (OS) of patients with bone metastasis.
Methods: From 1993 to 2011, 463 consecutive patients were treated for bone-metastatic prostate cancer. Data sets
from 361 patients were used to develop a nomogram (training data), and data sets of 102 patients were used for
validation of the nomogram (validation data). Using the external validation data set, the nomogram was assessed
for discriminatory ability, and the predictions were assessed for calibration accuracy by plotting actual survival
against predicted risk.
Results: Of the 361 patients in the training data set, 205 (56.8%) patients died, 169 (46.8%) deaths of which were due
to prostate cancer. The median follow-up period was 55.2 months. In the multivariate analysis, patient age, serum
prostate-specific antigen level, clinical T stage, extent of disease on bone scan, and biopsy Gleason sum were independent
prognostic factors. We developed a prognostic model comprising these five factors for patients with bone-metastatic
prostate cancer. This nomogram can be used to estimate 1-, 3-, and 5-year survival probability. External validation of this
model using 102 validation data sets showed reasonable accuracy (concordance index, 0.719).
Conclusion: Our pretreatment prognostic nomogram might be useful for Japanese patients with bone-metastatic
prostate cancer.
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Prostate cancer is the most common noncutaneous can-
cer, and the second most frequent cause of death from
cancer among men in the US. In Japan, 10,722 patients
(17.4 per 100,000) died of prostate cancer in 2010, mak-
ing this disease the sixth leading cause of cancer death
[1]. The incidence of prostate cancer is lower in Japan
than in the US and other Western countries; however,
its incidence has been gradually increasing in Japan in
recent years [1]. Huggins and Hodges [2] reported the
efficacy of androgen deprivation therapy for advanced
prostate cancer in 1941. Although 80–90% of prostate
cancers with metastasis respond to initial androgen abla-
tion therapy, most patients will ultimately develop* Correspondence: miyoyasu@med.yokohama-cu.ac.jp
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unless otherwise stated.progressive disease. Although some patients can obtain
benefit from second-line hormone therapy, anti-androgen
withdrawal therapy, new hormonal therapy such as enza-
lutamide and abiraterone, or chemotherapy, most patients
finally develop castration-resistant prostate cancer (CRPC)
[3,4]. Patients with CRPC show progression of systemic
symptoms and local complications. One report showed
that the median survival duration among patients with ad-
vanced prostate cancer was 29 to 34 months from initial
treatment [5], and another study reported a 5-year survival
rate of 20–30% [6]. Because these reports showed a wide
range of survival probability, more accurate information
on patient characteristics related to survival is needed.
In the US and Europe, some new effective agents for
CRPC have been approved, such as docetaxel, cabazitaxel,
sipuleucel-T, abiraterone, and enzalutamide [7-11]. Unfor-
tunately, treatment for CRPC was still very limited in Japan
until 2013 (cabazitaxel, abiraterone, and enzalutamide werel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[12]. Survival of patients with CRPC is predicted to im-
prove with the use of these drugs. Several groups have re-
ported prognostic models for survival of patients with
progressive disease. Almost all reports were of a prognostic
nomogram for patients with CRPC; there are few reports
about a prognostic nomogram for patients with metastatic
prostate cancer before treatment. A large study on the
prognosis of patients with pre-hormonal therapy prostate
cancer was reported in Japan and the US [13]; however, the
endpoint was not survival, but recurrence. Our interest is
in the development of an overall survival (OS) prognostic
model for hormone-naïve metastatic prostate cancer. Ac-
curate prediction models for prostate cancer survival
would be valuable for patient counseling. We analyzed the
relationship between prostate cancer outcomes and pre-
treatment clinical factors and developed a prognostic
nomogram for OS of patients with bone metastasis. Our
pretreatment prognostic nomogram might be useful for
Japanese patients with bone-metastatic prostate cancer.
Methods
Patients and treatments
From 1993 to 2011, 463 consecutive patients with bone-
metastatic prostate cancer were treated at Yokohama
City University Hospital and associated hospitals. All pa-
tients already had metastasis at the time of diagnosis,
and none of the patients had been previously treated.
The data sets of 361 patients from Yokohama City Med-
ical Center, Yokohama City University Hospital, Kana-
gawa Cancer Center, Minami Kyosai Hospital, Chigasaki
Hospital, and Fujisawa Municipal Hospital were used to
develop a nomogram (training data), and the data sets of
102 patients from Kawasaki Ida Hospital, International
Goodwill Hospital, and Yokosuka Kyosai Hospital were
used for validation of the nomogram (validation data).
All patients had adenocarcinoma of the prostate, con-
firmed histologically, with bone metastasis (any T, any
N, M1b). The 2009 TNM clinical staging system and
2005 International Society of Urologic Pathology Glea-
son grading system were used. In all patients, clinical
stage was evaluated by chest and body computed tomog-
raphy and bone scans. Based on the number or extent of
metastases, the scans were divided into the following five
grades according to the extent of disease on bone scan
(EOD) [14]: 0, normal or abnormal due to benign bone
disease; 1, fewer than 6 bony metastases, each of which
is less than 50% of the size of a vertebral body (1 lesion
about the size of a vertebral body was counted as 2 le-
sions); 2, from 6 to 20 bone metastases, sized as de-
scribed above; 3, more than 20 metastases but fewer
than seen in a “superscan”; and 4, “superscan” or its
equivalent, i.e., more than 75% of the ribs, vertebrae, and
pelvic bones.Docetaxel therapy was not included as a covariate be-
cause the nomogram was used as a tool to predict pre-
treatment survival.
Each hospital used the same treatment protocol. All
patients were initially treated with androgen deprivation
therapy (medical or surgical castration with or without
anti-androgen). After failed initial androgen ablation
therapy, almost all patients were subsequently under-
went substitution treatment comprising anti-androgen
therapy, anti-androgen withdrawal therapy, and/or oral
low-dose steroid therapy. Some patients received a bis-
phosphonate and cytotoxic therapy such as docetaxel or
estramustine after development of CRPC. In the ter-
minal state, palliative therapy and pain control with
morphine, palliative external beam radiation, and stron-
tium were used as appropriate.
Statistical analysis
The nomogram was developed using a Cox proportional
hazards regression model with stepwise regression ana-
lysis. The predictive variables for the nomogram were
patient age at initial treatment, serum prostate-specific
antigen (PSA) level before treatment, clinical T stage,
EOD to classify the extent of bone metastasis, and the
biopsy Gleason sum. Relative risks and 95% confidence
intervals were derived. The nomogram for OS was de-
veloped from the results of the Cox proportional hazards
model.
Calibration of the nomogram predictions was evalu-
ated by comparing the predicted probability at 5 years
with the Kaplan–Meier survival probability using the
training data (internal calibration). We also evaluated
the calibration by comparing the predicted probability at
3 years with the Kaplan–Meier survival probability using
the external validation data (external calibration). Using
the validation data set, the nomogram was assessed for
discriminatory ability by quantifying the concordance
index (c-index), and the predictions were assessed for
calibration accuracy by plotting actual survival against
predicted risk. The Kaplan–Meier product-limit estima-
tor was used to estimate the survival distribution. The
chi-squared test and Mann–Whitney U test were used
to assess the difference in baseline factors between the
training data set and the validation data set. The log-
rank test was used to analyze differences in survival
probability between the training data set and the valid-
ation data set. All tests were two-sided, and the signifi-
cance level was fixed at alpha = 0.05. All analyses were
conducted with IBM SPSS Statistics for Windows, ver. 19
(IBM Corp., Armonk, NY) and the R stats package (R
Foundation for Statistical Computing, Vienna, Austria).
Informed consent was obtained from all patients, and the
experimental procedures were conducted in accordance
with the ethical standards of the Helsinki Declaration.
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tutions’ review boards Yokohama City University Medical
Center, Yokohama City University Hospital, Yokohama
Minami Kyosai Hospital, Kanagawa Cancer Center,
Yokosuka Kyosai Hospital, Chigasaki Hospital, Kawasaki
Ida Hospital, International Goodwill Hospital, and
Fujisawa Municipal Hospital).Results
Training data
The pretreatment characteristics of the 361 patients in-
cluded in the training data set are listed in Table 1. Of
these patients, 205 (56.8%) died, 169 (46.8%) deaths of
which were due to prostate cancer. The median OS was
55.6 months (95%CI: 45.1-66.1), and the cause-specific
survival duration was 68.0 months (95%CI: 53.0-83.0).
The OS of the patients included in the training data set
is shown in Figure 1. In the training data set, 69 (19.1%)
patients received docetaxel for treatment of CRPC.Multivariate analysis
In the multivariate analysis, patient age at initial treat-
ment, pretreatment serum PSA level, clinical T stage,
EOD, and biopsy Gleason sum were independent prog-
nostic factors. Table 2 shows the results of the multivariate
analysis, on which the nomogram was based. These five
factors were included in the final nomogram. Figure 2
shows a nomogram that can predict the OS of patients
with bone-metastatic prostate cancer. This nomogram can
be used to estimate the 1-, 3-, and 5-year survival prob-
ability. Each scale position has corresponding prognos-
tic points located on the “Points” scale. To determine
the points of each factor, a vertical line is drawn from
each factor axis to the “Points” axis. The point values
for all five predictors are summed to arrive at the
“Total points” value.Table 1 Baseline characteristics of training and validation sam
Variables Training sampl
No. of patients 361
Age, years (mean, SD) 71.43 (8.68)
PSA, ng/mL (median, IQR) 253.8 (728.3-134
≤T3, T4 (%) 81.1, 18.9
EOD 1, 2, 3, 4 (%) 40.7, 26.6, 25.5, 7
Gleason ≤6, 7, 8-10 (%) 6.4, 18.6, 75.0
Use of docetaxel (%) 19.1





EOD: extent of disease on bone scan.Validation data
The pretreatment characteristics of the 102 patients in-
cluded in the training data set are listed in Table 1.
These data were obtained from three hospitals, including
one hospital that performed a docetaxel-related clinical
trial. Of these patients, 55 (53.9%) died, 44 (43.1%)
deaths of which were due to prostate cancer. The me-
dian OS was 48.3 months (95%CI: 36.1-60.5), and the
cause-specific survival was 54.9 months (95%CI: 43.8-
65.9). The OS for the patients in the validation data set
is shown in Figure 1. There was no difference in the OS
between the training data set and the validation set (p =
0.268). In the validation data set, 36 (35.3%) patients re-
ceived docetaxel for treatment of CRPC. The docetaxel-
use rate was significantly higher in the validation data
set than in the training data set (19.1%) (p < 0.0001).
Moreover, there were significant differences in the inci-
dence of clinical T4 disease between the training data
and the validation data (p < 0.0001).
We evaluated the discriminatory ability of the nomo-
gram by quantifying the c-index, and the predictions
were assessed for calibration accuracy by plotting actual
survival against predicted risk using the external valid-
ation data set. The c-index of the nomogram was 0.719.Internal and external validations
Internal and external validations were performed with
the method described by Iasonos et al. [15]. Figure 3
shows the internal calibration of the nomogram for 5-
year survival. The blue line indicates the ideal reference
line at which predicted probabilities match the observed
proportions. The dashes represent the nomogram-
predicted probabilities grouped for each of the four
quartile groups, along with the respective confidence in-
tervals. The predicted survival rate from the nomogram
was well correlated with the actual observation of 5-year
survival in the training data. Figure 4 shows the externalples
e Validation sample p value
102
70.39 (8.17) 0.309**
9.7) 358.0 (652.0-1597.2) 0.779**
62.8, 37.2 <0.0001*
.2 35.3, 27.5, 28.4, 8.8 0.764*
3.0, 16.7, 80.3 0.189*
35.3 <0.0001*
2.58 (2.58-3.51) 0.027**
Figure 1 Overall survival in training and validation samples obtained from Kaplan–Meier estimates.
Miyoshi et al. BMC Cancer  (2015) 15:338 Page 4 of 7calibration of the nomogram for 3-year survival. The
dashes represent the nomogram-predicted probabilities
grouped for each of the three tertile groups, along with
the respective confidence intervals. The predicted sur-
vival rate from the nomogram was also well correlated
with the actual observation of 3-year survival in the val-
idation data.Discussion
In this study, we developed a nomogram of OS of Japa-
nese patients with bone-metastatic prostate cancer. This
nomogram is an OS probability prediction tool compris-
ing five pretreatment prognostic factors selected by
multivariate analysis. These factors, namely patient age
at initial treatment, pretreatment serum PSA level, clin-
ical T stage, EOD, and biopsy Gleason sum, are common
clinical factors and may be useful for all patients.Table 2 Multivariate model predicting overall survival
Parameter p-value Hazard ratio HR lower CI HR upper CI
Age 0.0002 1.035 1.016 1.054
T stage 0.0002 1.882 1.345 2.634
EOD2 0.0221 1.552 1.065 2.260
EOD3 <.0001 2.472 1.664 3.673
EOD4 <.0001 4.042 2.291 7.132
Gleason score 0.0002 1.334 1.144 1.555
Log PSA 0.0023 0.712 0.572 0.886
EOD: extent of disease on bone scan.
GS: Gleason sum.
HR lower CI: hazard ratio, lower 95% confidential interval.
HR upper CI: hazard ratio, upper 95% confidential interval.It is crucial to test the Cox model for proportionality
of the hazards when building nomograms. We assessed
the proportional hazards assumption by testing the
interaction terms of the factors listed in Table 2 with
time. Some violation of the proportional hazards as-
sumption was evident (p = 0.012). However, if we in-
clude these interaction terms in the model, we cannot
present the results as a simple nomogram because the
effects of the covariates are time varying. Moreover, our
nomogram was well calibrated in the internal and exter-
nal data (Figures 3 and 4). Thus, we removed these
interaction terms from the model. We also conducted
multivariate analyses by treating age, log(PSA), and bi-
opsy Gleason as trichotomous categorical covariates
using tertiles as cut-off values. The estimated hazard ra-
tios of each variable were at least monotonically increas-
ing or decreasing over the categories, and thus we found
no evidences that our chosen functional forms were in-
appropriate. Thus, we used these factors as continuous
regressors.
Several groups have reported prognostic models for
survival of patients with progressive disease. Almost all
reports were of a prognostic nomogram of patients with
CRPC; there are few reports on prognostic nomograms
for hormone-naïve progressive prostate cancer before
treatment [16-19].
Hussain et al. [15] reported various risk predictors of
OS (SWOG9346). They identified baseline variables such
as bone pain, performance status, Gleason sum, weight
change, positive lymph node metastasis, pre-study PSA
increments, and PSA level after treatment as strong
prognostic factors for OS. Coopeberg et al. [13] also
Figure 2 Nomogram of prediction of OS in patients with bone-metastatic prostate cancer.
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hormone-naïve patients in Japan and the US. They
assessed 13,740 US men and 19,265 Japanese men with
prostate cancer and developed the Japan Cancer of the
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Figure 3 Internal calibration of nomogram of 5-year survival. The
predicted survival rate from the nomogram was well correlated with
the actual observation. The blue line indicates the ideal reference line
where the predicted probabilities match the observed proportions.
The dashes represent the nomogram-predicted probabilities grouped
for each of the four quartile groups, along with the respective
confidence intervals.which ranges from 0 to 12 and is based on the Gleason
sum, serum PSA level at initial treatment, and clinical
stage, can predict progression-free survival after primary
androgen deprivation therapy. Although the endpoint of
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Figure 4 External calibration of nomogram for 3-year survival. The
predicted survival rate from the nomogram was well correlated with
the actual observation. The blue line indicates the ideal reference line
where the predicted probabilities match the observed proportions.
The dashes represent the nomogram-predicted probabilities grouped
for each of the three tertile groups, along with the respective
confidence intervals.
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tients with hormone-naïve metastatic prostate cancer.
Progression-free survival has been shown to be predictive
of OS in men with CRPC [20], although the association
between progression-free survival and OS is relatively
weak. Some reports have indicated improvement in OS
without an increase in progression-free survival [9] or im-
provement in progression-free survival without an in-
crease in survival [21]. Accurate prediction models for
prostate cancer survival probability would be valuable for
patient counseling.
We analyzed the relationship between prostate cancer
outcomes and pretreatment clinical factors and devel-
oped a prognostic nomogram of the OS of patients with
bone metastasis. Recently, there has been rapid develop-
ment in treatment for CRPC. In the US and other Western
countries, some new effective agents for CRPC have been
approved, such as docetaxel, cabazitaxel, sipuleucel-T, abir-
aterone, and enzalutamide [7-11,22]. Unfortunately, treat-
ment for CRPC was still very limited in Japan until 2013
(cabazitaxel, abiraterone, and enzalutamide were approved
in 2014), although docetaxel has been approved [12]. These
agents could improve the survival of patients with CRPC.
External validation of this nomogram was performed
using the validation data set of 102 cases. The predicted
survival rate calculated by our nomogram was well cor-
related with practical observation. The docetaxel-use
rate was significantly higher in the validation data set
than in the training data set (p < 0.0001). Moreover,
there were significant differences in incidence of clinical
T4 disease between the training data and the validation
data (p < 0.0001), although our nomogram was well cor-
related with actual observations.
As mentioned above, the first limitation of this study
is that our nomogram was developed from data from the
“pre-docetaxel era” or “docetaxel era.” For more accurate
prediction for patients with prostate cancer in the “post-
docetaxel era,” more recently collected data are needed.
Moreover, validation samples collected from a non-
Japanese population would provide wider applicability.
The second limitation of this study is the fact that pa-
tients enrolled in the study had various health statuses
and complications. Our nomogram considers neither
health status nor patient complications that may influ-
ence prostate cancer treatment outcomes [15,23,24]. Pa-
tients with prostate cancer are much older than those
with other malignancies. Health status and complica-
tions should be classified in the rating score and in-
cluded as predictive factors in the nomogram. Bone pain
at diagnosis is also strong predictor of OS [15]. Unfortu-
nately, data regarding pain at baseline were not available
in this study.
The final limitation of this study is the lack of data
about serum hemoglobin, lactate dehydrogenase, andalkaline phosphatase levels. These factors have been re-
ported as predictive factors for patients with CRPC
[18,19,25].
In conclusion, we developed a prognostic model for
patients with bone-metastatic prostate cancer. This
model could predict OS from five pretreatment factors,
namely patient age at initial treatment, pretreatment
serum PSA level, clinical T stage, EOD, and biopsy Glea-
son sum, in patients with bone-metastatic prostate can-
cer. External validation of this model showed it to be
reasonably accurate and similar to practical actual sur-
vival probability.
Conclusion
Our pretreatment prognostic nomogram might be useful
for Japanese patients with bone-metastatic prostate cancer.
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